Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-c…
| Periodo | 2026-11 | 2026-09 |
|---|---|---|
| Real | — | $-2.62 |
| Estimado | $-1.03 | $-3.72 |
| Sorpresa | — | +29.6% |
| Métrica | SCTX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | — | -34.4% | — |
| Net Margin | — | -32.5% | — |
| FCF Margin | — | -12.6% | — |
| ROE | — | -39.2% | — |
| ROA | — | -30.9% | — |
| Current Ratio | — | 2.73 | — |
| Debt / Equity | — | 0.28 | — |
Scribe Therapeutics, Inc. cotiza a 20.08 USD y tiene una capitalización bursátil de $380M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud